PAVmed Raises $45M to Clear Legacy Capital and Boost EsoGuard Commercialization
- PAVmed issued $30M Series D and a $15M secured note to redeem Series C and convertible debt, removing legacy overhang.
- Warrants tied to a positive Medicare LCD could fund up to an additional $30M, linking equity to reimbursement progress.
- PAVmed will seek shareholder approval to convert Series D at $6.50, leaving $7.7M net cash now, $37.7M potential.
PAVmed closes financing to clear legacy capital roadblocks and back EsoGuard rollout
Capital restructuring to accelerate EsoGuard commercialization
PAVmed Inc. is closing a financing package aimed at simplifying its capitalization and accelerating commercialization of the EsoGuard esophageal DNA test marketed by subsidiary Lucid Diagnostics. The company issues $30 million of Series D convertible preferred stock and concurrently takes a $15 million senior secured note due February 2029, using the proceeds to redeem and retire all outstanding Series C preferred stock and convertible debt. Management says this eliminates a significant legacy capital structure overhang that has hindered strategic execution.
The deal includes warrants tied to regulatory progress: investors receive warrants exercisable for as much as an additional $30 million of Series D if a positive draft Medicare local coverage determination (LCD) for EsoGuard is published. PAVmed frames the structure as conditional growth capital that links further equity issuance to reimbursement momentum, which is critical for broader clinical adoption of a diagnostic assay that targets early detection of esophageal disease.
Executives stress that simplifying the capitalization reduces near‑term refinancing needs and dilution risk, thereby allowing Lucid to focus on reimbursement, commercialization and clinical adoption. By retiring prior convertible securities, PAVmed expects to provide clearer visibility into future equity value and to give management greater flexibility to execute marketing, payer engagement and distribution initiatives for EsoGuard.
Shareholder conversion vote and support
PAVmed schedules a special meeting of stockholders no later than April 30, 2026 to seek approval to convert the Series D preferred into common stock at a conversion price of $6.50 per share. The company reports voting agreements from holders representing roughly 25% of its outstanding common stock in support of the proposal, a step management says is intended to enable a “clean” capital structure composed of common equity and long‑term debt if the warrants are exercised and conversion is approved.
Proceeds, investor base and operational impact
The combined financings generate a $22.3 million cash payment and the $15 million long‑term note used for redemption, leaving about $7.7 million in net cash for working capital after retirements. The financings come from existing long‑term investors and are described as strengthening the balance sheet; assuming full exercise of warrants upon a positive EsoGuard LCD and subsequent conversion, PAVmed would add roughly $37.7 million in cash and move to a simplified capital structure expected to support reimbursement negotiations and commercial scale‑up.